Starling Oncology Reports Record Q3 Revenue of $169.8 Million and Provides 2026-2027 Guidance
Starling Oncology (STLN) reported record third-quarter revenue of $169.8 million, representing a 24% increase year-over-year. The company also achieved an adjusted EBITDA of $3.4 million for the quarter, marking its second consecutive period of positive adjusted EBITDA. Looking ahead, management issued long-term financial guidance projecting revenue between $650 million and $660 million with an adjusted EBITDA of $4 million to $6 million for fiscal year 2026. Furthermore, the company is targeting aggressive growth in 2027, aiming for a 100% increase in capitated revenue.
Topics: earnings report EBITDA financial results revenue growth
Read the full article at Seeking Alpha
Part of the story Mach Natural Resources Reports Q3 2026 Results and Provides 2027 Guidance (13 articles)